Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis - PubMed (original) (raw)

Review

Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

Xiaoning Gan et al. Dis Markers. 2016.

Abstract

p16, encoded by the CDKN2A gene, is a tumor suppressor that has been widely studied in cancer research. However, the relationship of p16 with prognostic and clinicopathological parameters in patients with bladder cancer remains unclear. Data inclusion criteria were articles reporting on the relationship between p16 expression and the prognosis or clinicopathology in patients with bladder cancer. Meta-analyses were performed with Stata software. Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated to evaluate the relative risks. The source of heterogeneity was analyzed by subgroup analysis. A total of 37 studies with 2246 cases were included and analyzed. The results identified an important link between downregulated p16 expression and poor prognosis in patients with bladder cancer in terms of recurrence-free survival (RFS), overall survival (OS), progression-free survival (PFS), and some clinicopathological parameters including clinical staging, pathological degree, and lymph node metastasis. Subgroup analysis also showed that low p16 expression could function as a warning sign for RFS and PFS in patients with early-stage (Ta-T1) bladder cancer. In conclusion, p16 might play an essential role in the deterioration of bladder cancer and could serve as a biomarker for the prediction for patients' progression and prognosis.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Main molecular pathways of bladder cancer (adapted from Mitra et al. [7]).

Figure 2

Figure 2

Flow diagram of studies selection procedure.

Figure 3

Figure 3

Forrest plot of hazard ratio (HR) for the association of p16 with recurrence-free survival (RFS) (a), overall survival (OS) (b), and progression-free survival (PFS) (c) in patients with bladder cancer.

Figure 4

Figure 4

The funnel plot of the meta-analysis of the impact of p16 expression on recurrence-free survival (RFS) (a), overall survival (OS) (b), and progression-free survival (PFS) (c) in patients with bladder cancer.

Figure 5

Figure 5

Our results illustrated and improved the relationship between p16 and prognosis, as well as clinicopathological features.

Similar articles

Cited by

References

    1. Ploeg M., Aben K. K. H., Kiemeney L. A. The present and future burden of urinary bladder cancer in the world. World Journal of Urology. 2009;27(3):289–293. doi: 10.1007/s00345-009-0383-3. - DOI - PMC - PubMed
    1. Kaufman D. S., Shipley W. U., Feldman A. S. Bladder cancer. The Lancet. 2009;374(9685):239–249. doi: 10.1016/S0140-6736(09)60491-8. - DOI - PubMed
    1. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–707. doi: 10.1038/366704a0. - DOI - PubMed
    1. Orlow I., LaRue H., Osman I., et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. The American Journal of Pathology. 1999;155(1):105–113. doi: 10.1016/s0002-9440(10)65105-x. - DOI - PMC - PubMed
    1. Krüger S., Mahnken A., Kausch I., Feller A. C. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. European Urology. 2005;47(4):463–467. doi: 10.1016/j.eururo.2004.12.018. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources